Page 17 of 76
Previous Page     Next Page        Smaller fonts | Larger fonts     Go back to the flash version
Genz_ad.qxp 4/2/08 03:18 Page 15
Start now and shape the future
Start with Renagel and you’re planning
for your patients’ future. Renagel
1
controls serum phosphorus within
2
the KDOQI target range without any
3
risk of calcium or metal accumulation.
Sevelamer is a KDOQI-recommended
2
first-line treatment option. Renagel
is the only phosphate binder proven to
2,3
reduce LDL-cholesterol by up to 31%.
1SPEVDU 4VNNBSZ3FOBHFM
¡
 NHàMNDPBUFEU"DUJBWCF MTFVCTUBODFUT TFWFMBNFS GSPN UIFTF TUVEJFT  QBUJFOUT
BOE GSPN VODPOUSPMMFE DMJOJDBM USJBMT QBUJFOUT
BSF
4VCKFDU UP NFEJDBM QSFTDSJQUJPO$PNQPT JUJPO&BDI UBCMFUDPOUBJOTNHTMJTUFFEWFCMZBGSNFRVFODZFSIFSF OFYU (BTUSPJOUFTUJOBM EJTPSEFST OBVTFB
WUJOH
PNJ BCEPNJOBM
&BDI UBCMFUBMTPDPOUBJOTTJMJDB
DPMMPJEBMBOIFIZUBECMFUSPDVPBTUJOHBOQBJOET
UDFPOTUJQBBSJDUJPOB
DEJBJESSIPFB
5 EZTQFQTJB WFSZ DPNNPO
BOE áBUVMFODFPNNPO D
 /FSWPVT
DPOUBJOT IZQSPNFMMPTF BOE EJBDFUZMBUFE NPOPHMZDFSJEFT 5IF QSJOUJOHLDJO POUBJOTJTZTUFNSPEJTPSEFSO T IFBEBDIF WFSZ DPNNPO
 7BTDVMBS EJTPSEFST IZQPUFOTJPO
IZQFSUFOTJPO
PYJEF CMBDL &

QSPQZMFOFHMZDPMBOEIZQ5ISPFSNBQFFVUJDMMPTJFOEJDBUJPOT 3FOB HFM
¡
WFSZ DPNNPO
(FOFSTPSEFBMESJT BOE BENJOJTUSBUJPO TJUF DPOEJUJPOTJOQB WFSZ DPNNPO

JT JOEJDBUFE GPS UIFDPOUSPMPGIZQFSQIPTQIBUBFNJBJOJWJOHBEVIMUQBFNPEJBMZBUJFOTJTUTS 4LFDJOFBOE TVCDVUBOFPVT EJTPSEFST QSVSJUJT WFSZ DPNNPO
BOE SBTI DPNNPO
 *OGFDUJPOT
PS QFSJUPOFBM EJBMZTJT 3FOBH
¡
FMTIPVME CF VTFE XJUIJO UIF DPOUFYU PG B NVMUJQMF UIFSBQFVUJDBOE JOGFTUBUJPOT QIBSZOHJUJT DPNNPO
 5IF SFQPSUJOH SBUF JT DMBTTJGJFEBTWFSZDPNNPO
BQQSPBDI
XIJDI DPVME JODMVEF DBMDJVN TVQQMFNFOUT

EJIZESPYZNJO7JUB% PS POF \

DPNNPO \


VOD PNNPO \


S
BSF 
\




PG JUT BOBMPHVFT UP DPOUSPM UIF EFWFMPQNFOU PG SFOBM CPOF EJTFBTF$POU SBJOEJDBUJPOT WFSZ SBSF 


JODMVEJOH JTBUFPM E .PTUPGUIFTFFWFOUOMZTBPCSTFSFDWFEP NNP
)ZQPQIPTQIBUBFNJB PS CPXFM PCTUSVDJPOU  )ZQFSTFOTJUJWJUZ UP TFWFMBNFSPS UP BOZ PGUIFJO QBUJFOUT XJUI 4UBHF  $ISPOJD ,JEOF%JTZ FBTF BOEBSF OPU OFDFTTBSJMZ BUSJCVU UBCMF UP
FYDJQJFOUT JOUIF QSPEVDU1PTTJCMF TJEF FGGFDUT*O QBSBMMFM EFTJHO TUVEJFT JOWPMWJOH  3FOBHFM
¡
 1PTUNBSLFUJOH FYQFSJFODF*O WFSZ SBSF DBTFT
JOUFTUJOBM PCTUSVDUJPO BOE JMFVT
IBFNPEJBMZTJT QBUJFOUT XJUI USFBUNFOUEVSBUJPOPGXFFFBMLTBEJBMZOTJTE TVCJMFVTQFSIBJWUFPCFFOO PCTFSWFE JO QBFOUTUJ EVSJOH USFBUNFOU XJUI 3FOBH
¡
FM 1SPEVDU -JDFODF
QBUJFOUT XJUI USFBUNFOU EVSBUJPOGP XFFLT
UIF NPTU GSFRVFOUMZ PDDVSOHSJ \ PG IPMEFS(FO[ZNF &VSPQF #7
(PPJNFFS 
 %% /BBSEFO
5IF /FUIFSMBOE%BTUF PG
QBUJFOUT
VOEFTJSBCMF FGGFDUT QPTTJCMZ PSQSPCBCMZSFMB
¡
UXFSFEUF BMMP3JO UIF OSFBWJTJPOHFMPG UFYUTU +VOF
HBTUSPJOUFTUJOBM EJTPSEFST TZTUFNPSHBO DMBTT %BUB QPTTJCMZ PS QSPCBCMZSFMBUFP3EUFBHOFM
¡
"UUFOUJPO1MFBTFTFF GVMM QSFTDSJCJOH JOGPSNBUJPO
References:
1. Chertow GM et al. Kidney Int 2002;62:245-252.
2. National Kidney Foundation. KDOQI Clinical Practice Guidelines for Bone Metabolism and
Disease in Chronic Kidney Disease. AmJKidneyDis2003;42(Suppl 3):S1-S201.
3. Renagel Summary of Product Characteristics.
© 2007, Genzyme Corporation. All rights reserved. RP142/6 07/07
Previous arrowPrevious Page     Next PageNext arrow        Smaller fonts | Larger fonts     Go back to the flash version
1  |  2  |  3  |  4  |  5  |  6  |  7  |  8  |  9  |  10  |  11  |  12  |  13  |  14  |  15  |  16  |  17  |  18  |  19  |  20  |  21  |  22  |  23  |  24  |  25  |  26  |  27  |  28  |  29  |  30  |  31  |  32  |  33  |  34  |  35  |  36  |  37  |  38  |  39  |  40  |  41  |  42  |  43  |  44  |  45  |  46  |  47  |  48  |  49  |  50  |  51  |  52  |  53  |  54  |  55  |  56  |  57  |  58  |  59  |  60  |  61  |  62  |  63  |  64  |  65  |  66  |  67  |  68  |  69  |  70  |  71  |  72  |  73  |  74  |  75  |  76